Ravgen

Executive Summary

Ravgen is a US-based biotechnology company specializing in non-invasive prenatal testing (NIPT) and paternity DNA testing. Founded in 2000 and headquartered in Columbia, Maryland, the company has developed proprietary technology to increase the fraction of analyzable fetal DNA from maternal blood, enabling safer and highly accurate screening for chromosomal abnormalities and single-gene disorders. Unlike traditional invasive procedures such as amniocentesis, Ravgen's tests carry no risk of miscarriage, positioning the company as a key player in the rapidly growing NIPT market. The company operates in the genetics and diagnostics sectors, with a focus on improving prenatal care through non-invasive methods. Ravgen's technology addresses a critical limitation in NIPT: low fetal DNA fraction, which can lead to test failure or inaccurate results. By enhancing the yield of fetal DNA, Ravgen improves test sensitivity and reduces the need for repeat draws. The global NIPT market is expected to exceed $6 billion by 2030, driven by increasing maternal age, rising awareness, and reimbursement expansion. Ravgen's long track record and established presence in the US provide a competitive advantage. However, the company remains private, and financial details are limited. The conviction score reflects the potential of Ravgen's technology and market opportunity, tempered by the lack of recent disclosures and competitive pressure from larger players like Illumina and Natera.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Expanded NIPT Panel70% success
• Q4 2026Strategic Partnership or Licensing Deal with Major Lab60% success
• Q2 2026Publication of Clinical Validation Study in Peer-Reviewed Journal80% success